Skip to content

Sagimet Biosciences

US · SGMT #3599 by market cap Listed 2023
8.88 +0.12 +1.37%
Live - 5344 symbols - heartbeat 118s ago · 2026-10-08 09:10
Pre-market 8.96 +0.90%
After-hours 8.88 0.00%
Market cap
629.67M
P/B
2.46
EPS
-1.58
Reader sentiment Are you bullish or bearish on SGMT?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 2.46 Expensive vs history 87th percentile
5-year average 1.35 · #260 of 513 in Biotechnology
P/E ratio -7.05 Cheap vs history 13th percentile
5-year average -4.74 · forward -8.23
P/S ratio 314.83 Expensive vs history 96th percentile
5-year average 98.58 · forward 351.28 · #318 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Sagimet Biosciences (SGMT) 629.67M -7.05 2.46 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value11.36 Economic moatNone UncertaintyVery High

Trading 28.0% below Morningstar's fair value estimate.

Fair value

Sagimet Biosciences Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 22% discount to our quantitative fair value estimate of $11.36 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet strengthens our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio lies in the top 1% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.6, for example, ranks in the bottom 10% globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 09:10:25 · For reference only, not investment advice and not tailored to your situation.